Bio-Rad Laboratories A
BIO
Bio-Rad Laboratories A (BIO) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $2.62
- EPS estimate
- $1.75
- EPS surprise
- +49.92%
- Revenue surprise
- +4.33%
- Revenue
- $651.0M
- Revenue estimate
- $624.0M
- Reported
- Aug 4, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 4, 2026 | $1.75 | $2.62 | +49.92% | $651.0M | SEC |
| Q1 2026 | Apr 30, 2026 | $1.97 | $1.89 | −4.21% | $592.1M | SEC |
| Q4 2025 | Feb 12, 2026 | $2.71 | $2.51 | −7.31% | $693.2M | SEC |
| Q3 2025 | Oct 29, 2025 | $1.95 | $2.26 | +15.66% | $653.0M | SEC |
| Q2 2025 | Jul 31, 2025 | $1.73 | $2.61 | +50.52% | $651.6M | SEC |
| Q1 2025 | May 1, 2025 | $1.81 | $2.54 | +40.31% | $585.4M | SEC |
| Q4 2024 | Feb 13, 2025 | $2.87 | $2.90 | +1.10% | $667.5M | SEC |
| Q3 2024 | Oct 30, 2024 | $1.16 | $2.01 | +73.70% | $649.7M | SEC |
| Q2 2024 | Aug 1, 2024 | $2.01 | $3.11 | +54.38% | $638.5M | SEC |
| Q1 2024 | May 7, 2024 | $2.15 | $2.29 | +6.70% | $610.8M | SEC |
| Q4 2023 | Feb 15, 2024 | $2.82 | $3.10 | +10.00% | $681.2M | SEC |
| Q3 2023 | Oct 26, 2023 | $2.78 | $2.33 | −16.25% | $632.1M | SEC |
| Q2 2023 | Aug 3, 2023 | $2.68 | $3.00 | +11.98% | $681.1M | SEC |
| Q1 2023 | May 4, 2023 | $3.54 | $3.34 | −5.71% | $676.8M | SEC |
| Q4 2022 | Feb 16, 2023 | $3.45 | $3.31 | −4.01% | $730.3M | SEC |
| Q3 2022 | Oct 27, 2022 | $2.78 | $2.60 | −6.55% | $680.8M | — |
| Q2 2022 | Jul 28, 2022 | $2.80 | $3.38 | +20.77% | $691.1M | — |
| Q1 2022 | Apr 28, 2022 | $3.37 | $4.94 | +46.64% | $700.1M | — |
| Q4 2021 | Feb 10, 2022 | $2.85 | $3.21 | +12.60% | $732.8M | — |
| Q3 2021 | Oct 28, 2021 | $2.44 | $3.71 | +52.22% | $747.0M | — |
Quarterly revenue
Frequently asked questions
When did Bio-Rad Laboratories A (BIO) last report earnings?
Bio-Rad Laboratories A last reported on Aug 4, 2026, covering fiscal Q2 2026.
Did BIO beat earnings estimates?
Yes. Bio-Rad Laboratories A reported EPS of $2.62 for Q2 2026 against a $1.75 estimate — a 49.92% beat.
How much revenue did BIO report last quarter?
Bio-Rad Laboratories A reported $651.0M in revenue for Q2 2026, against a consensus estimate of $624.0M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.